NCT04760743View on ClinicalTrials.gov

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

April 2, 2021

Study Completion Date

March 2, 2022

Conditions
COVID-19 (Healthy Volunteers)
Interventions
BIOLOGICAL

NBP2001 adjuvanted with alum (RBD 30μg/dose)

Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.

BIOLOGICAL

NBP2001 adjuvanted with alum (RBD 50μg/dose)

Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.

OTHER

Normal Saline

Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

Trial Locations (2)

Unknown

Seoul National University Bundang Hospital, Seongnam-si

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

SK Bioscience Co., Ltd.

INDUSTRY

NCT04760743 - Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19) | Biotech Hunter | Biotech Hunter